Dhivy is a drug owned by Avion Pharmaceuticals Llc. It is protected by 3 US drug patents filed from 2022 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 28, 2039. Details of Dhivy's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11033521 | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | Active |
| US11819485 | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | Active |
| US11439613 | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dhivy's patents.
Latest Legal Activities on Dhivy's Patents
Given below is the list of recent legal activities going on the following patents of Dhivy.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 21 Nov, 2023 | US11819485 |
| Patent eGrant Notification | 21 Nov, 2023 | US11819485 |
| Mail Patent eGrant Notification | 21 Nov, 2023 | US11819485 |
| Recordation of Patent Grant Mailed Critical | 21 Nov, 2023 | US11819485 |
| Recordation of Patent eGrant | 21 Nov, 2023 | US11819485 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Nov, 2023 | US11819485 |
| Email Notification Critical | 02 Nov, 2023 | US11819485 |
| Issue Notification Mailed Critical | 01 Nov, 2023 | US11819485 |
| Application Is Considered Ready for Issue Critical | 16 Oct, 2023 | US11819485 |
| Dispatch to FDC | 16 Oct, 2023 | US11819485 |
US patents provide insights into the exclusivity only within the United States, but Dhivy is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Dhivy's family patents as well as insights into ongoing legal events on those patents.
Dhivy's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Dhivy's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 28, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Dhivy Generic API suppliers:
Carbidopa; Levodopa is the generic name for the brand Dhivy. 22 different companies have already filed for the generic of Dhivy, with Impax Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Dhivy's generic
Alternative Brands for Dhivy
Dhivy which is used for treating Parkinson's disease and related conditions., has several other brand drugs using the same active ingredient (Carbidopa; Levodopa). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Carbidopa; Levodopa, Dhivy's active ingredient. Check the complete list of approved generic manufacturers for Dhivy
About Dhivy
Dhivy is a drug owned by Avion Pharmaceuticals Llc. It is used for treating Parkinson's disease and related conditions. Dhivy uses Carbidopa; Levodopa as an active ingredient. Dhivy was launched by Avion Pharms in 2021.
Approval Date:
Dhivy was approved by FDA for market use on 12 November, 2021.
Active Ingredient:
Dhivy uses Carbidopa; Levodopa as the active ingredient. Check out other Drugs and Companies using Carbidopa; Levodopa ingredient
Treatment:
Dhivy is used for treating Parkinson's disease and related conditions.
Dosage:
Dhivy is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 25MG;100MG | TABLET | Prescription | ORAL |